AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs
Meet us at the 2018 Bio Convention to be held in Boston
17 June 2018
PRESS RELEASE – IL-17 patent granted in Europe
27 October 2018
On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.
